Cardiff Oncology, Inc.
CRDF- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001213037
In the last 90 days, Cardiff Oncology, Inc. insiders filed 2 open-market purchases and 0 sales; 104 institutions reported holding it in 13F filings for Q2 2026, worth $24.2M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Cardiff Oncology, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 83 | 117 | +34 |
| Shares | 12.8M | 28.1M | +15.3M (+120.1%) |
| Value | $34.1M | $121.9M | +$87.8M (+257.8%) |
New holders (37)
Institutions that held Cardiff Oncology, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
Sold out (3)
Institutions that held Cardiff Oncology, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| BIT Capital GmbH | 253,085 | $675.7K |
| Cetera Investment Advisers | 38,000 | $101.5K |
| Qube Research & Technologies Ltd | 37,245 | $99.4K |